CY1115338T1 - Χρηση ενος ή ενος συνδυασμου φυτο-κανναβινοειδων στην θεραπεια της επιληψιας - Google Patents

Χρηση ενος ή ενος συνδυασμου φυτο-κανναβινοειδων στην θεραπεια της επιληψιας

Info

Publication number
CY1115338T1
CY1115338T1 CY20141100335T CY141100335T CY1115338T1 CY 1115338 T1 CY1115338 T1 CY 1115338T1 CY 20141100335 T CY20141100335 T CY 20141100335T CY 141100335 T CY141100335 T CY 141100335T CY 1115338 T1 CY1115338 T1 CY 1115338T1
Authority
CY
Cyprus
Prior art keywords
cbd
thcv
plant
cannivoid
combination
Prior art date
Application number
CY20141100335T
Other languages
English (en)
Inventor
Ben Whalley
Gary Stephens
Claire Williams
Geoffrey Guy
Stephen Wright
Tetsuro Kikuchi
Original Assignee
Gw Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41008705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115338(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gw Pharma Limited filed Critical Gw Pharma Limited
Publication of CY1115338T1 publication Critical patent/CY1115338T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Χρήση του tetrahydrocannabivarin (THCV) είτε μόνου ή που περιλαμβάνει περαιτέρω cannabidiol (CBD) στην θεραπεία της επιληψίας και ειδικότερα στην θεραπεία γενικευμένων επιληπτικών κρίσεων. Μία υλοποίηση σχετίζεται με την χρήση του κανναβινοειδούς THCV σαν καθαρής ή απομονωμένης ένωσης, ή σαν φυτικού εκχυλίσματος στο οποίο σημαντικές ποσότητες οποιουδήποτε φυσικά παρόντος THC έχουν επιλεκτικά απομακρυνθεί. Σε μία περαιτέρω υλοποίηση, το THCV ή το εκχύλισμα που περιέχει THCV αναμιγνύεται με CBD ή ένα εκχύλισμα πλούσιο σε CBD ώστε να επωφελείται από την αντί-επιληπτική δραστικότητα του CBD.
CY20141100335T 2009-07-03 2014-05-12 Χρηση ενος ή ενος συνδυασμου φυτο-κανναβινοειδων στην θεραπεια της επιληψιας CY1115338T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0911580A GB2471523A (en) 2009-07-03 2009-07-03 Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
EP10734541.5A EP2448637B2 (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy

Publications (1)

Publication Number Publication Date
CY1115338T1 true CY1115338T1 (el) 2017-01-04

Family

ID=41008705

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100335T CY1115338T1 (el) 2009-07-03 2014-05-12 Χρηση ενος ή ενος συνδυασμου φυτο-κανναβινοειδων στην θεραπεια της επιληψιας

Country Status (29)

Country Link
US (4) US9066920B2 (el)
EP (3) EP3718603A1 (el)
JP (2) JP5904938B2 (el)
KR (1) KR101727000B1 (el)
CN (2) CN102596322A (el)
AR (1) AR077448A1 (el)
AU (1) AU2010267775C1 (el)
BR (1) BR112012000076A2 (el)
CA (2) CA2766082C (el)
CY (1) CY1115338T1 (el)
DK (1) DK2448637T4 (el)
ES (1) ES2460623T5 (el)
GB (3) GB2471523A (el)
HK (1) HK1164766A1 (el)
HR (1) HRP20140398T4 (el)
IL (1) IL217280B (el)
IN (1) IN2012DN00804A (el)
MX (1) MX2012000257A (el)
MY (1) MY156759A (el)
NZ (2) NZ597704A (el)
PL (1) PL2448637T5 (el)
PT (1) PT2448637E (el)
RU (1) RU2563143C2 (el)
SG (1) SG176914A1 (el)
SI (1) SI2448637T2 (el)
TW (1) TWI461191B (el)
UA (1) UA108852C2 (el)
WO (1) WO2011001169A1 (el)
ZA (1) ZA201200373B (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
KR20070089151A (ko) 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) * 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2479153B (en) * 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) * 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
US10117891B2 (en) 2014-09-16 2018-11-06 India Globalization Capital, Inc. Cannabinoid composition for treating pain
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
US10751300B2 (en) 2015-01-25 2020-08-25 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
CA2974292C (en) 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
WO2016160542A1 (en) * 2015-04-01 2016-10-06 India Globalization Capital, Inc. Composition and method for treating seizure disorders
EP3288592A4 (en) * 2015-04-28 2019-01-09 The Regents of The University of California USE OF CANNABIDIOL FOR THE TREATMENT OF CHILDREN'S SPAS
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2017027651A1 (en) 2015-08-12 2017-02-16 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
AU2016359160A1 (en) 2015-11-24 2018-06-14 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
EP3478307A4 (en) 2016-06-29 2020-02-26 Cannscience Innovations Inc. DECARBOXYLATED CANNABIS RESINS, USES AND METHODS OF MAKING
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN108236608B (zh) * 2016-12-27 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
CN108245510B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
CN108245499B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途
CN108245517B (zh) * 2016-12-29 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与拉莫三嗪的药物组合物及其用途
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
CN108785298A (zh) * 2017-04-27 2018-11-13 汉义生物科技（北京）有限公司 一种用于治疗癫痫的药物组合物、其制备方法及用途
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB2583526A (en) 2019-05-03 2020-11-04 Gw Res Ltd Use of cannabidiol in the treatment of tuberous sclerosis complex
CN110101804A (zh) * 2019-05-30 2019-08-09 厦门梓素生物科技有限公司 一种含大麻二酚提取物的癫痫药物组合及其制备方法
JP2022547136A (ja) * 2019-09-17 2022-11-10 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 発達性及びてんかん性脳症における行動障害の治療
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
EP3912485A1 (en) 2020-05-18 2021-11-24 Del-Vis Sp. z o.o. Cigarette product and a method for manufacturing the product
GB2597279A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
CA3187303A1 (en) 2020-07-28 2022-02-03 Impello Biosciences, Inc. Methods and compositions for altering secondary metabolites in plants
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
GB2604132A (en) 2021-02-25 2022-08-31 Gw Res Ltd Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes
US11337934B1 (en) 2021-04-08 2022-05-24 Lanny Leo Johnson Compositions including a cannabinoid and protocatechuic acid
WO2023009817A2 (en) 2021-07-29 2023-02-02 Emory University Phosphate prodrugs of cannabinoids
WO2023200906A1 (en) * 2022-04-12 2023-10-19 Shackelford Pharma Inc. Treatment of seizure disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
CA2438097C (en) * 2001-02-14 2006-04-25 Gw Pharma Limited Cannabinoids pharmaceutical formulations
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
ITPD20020138A1 (it) 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
KR101008609B1 (ko) * 2002-08-14 2011-01-17 지더블유 파마 리미티드 점막투여용 칸나비노이드 액체 제형
CA2994322A1 (en) 2002-08-14 2004-02-14 Gw Pharma Limited Botanical drug substances comprising various proportions of thc and cbd
KR20070089151A (ko) * 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
WO2007142957A2 (en) 2006-05-30 2007-12-13 Air Systems Gear drive damper
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
WO2009120080A1 (en) 2008-03-26 2009-10-01 Mareda Holding Bv Chewing gum compositions comprising cannabinoids
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
EP2747770A1 (en) 2011-08-26 2014-07-02 BIAL - Portela & Cª S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US20150181924A1 (en) 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
WO2015142501A1 (en) 2014-03-21 2015-09-24 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
CN106999598B (zh) 2014-05-29 2022-02-08 鲜切发展有限责任公司 稳定的大麻素类化合物制剂
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
ES2460623T5 (es) 2022-10-14
US20150335590A1 (en) 2015-11-26
AU2010267775C1 (en) 2020-02-27
US20170273913A1 (en) 2017-09-28
EP2448637B2 (en) 2022-06-08
US9066920B2 (en) 2015-06-30
BR112012000076A2 (pt) 2020-06-02
EP2727626A1 (en) 2014-05-07
SI2448637T1 (sl) 2014-07-31
PL2448637T3 (pl) 2014-08-29
NZ597704A (en) 2014-05-30
SG176914A1 (en) 2012-01-30
JP2012532093A (ja) 2012-12-13
ES2460623T3 (es) 2014-05-14
GB2471565A (en) 2011-01-05
RU2012103603A (ru) 2013-08-10
WO2011001169A1 (en) 2011-01-06
AR077448A1 (es) 2011-08-31
AU2010267775A1 (en) 2012-02-23
TWI461191B (zh) 2014-11-21
CN106236744A (zh) 2016-12-21
EP2448637A1 (en) 2012-05-09
JP2016166205A (ja) 2016-09-15
HRP20140398T1 (hr) 2014-06-20
US9522123B2 (en) 2016-12-20
GB2485291B (en) 2013-03-27
AU2010267775B2 (en) 2016-10-06
CA2766082C (en) 2019-06-11
CN102596322A (zh) 2012-07-18
GB201121919D0 (en) 2012-02-01
HRP20140398T4 (hr) 2022-10-14
DK2448637T4 (da) 2022-09-12
TW201105318A (en) 2011-02-16
GB201010897D0 (en) 2010-08-11
SI2448637T2 (sl) 2022-10-28
RU2563143C2 (ru) 2015-09-20
KR101727000B1 (ko) 2017-05-02
PT2448637E (pt) 2014-05-27
GB0911580D0 (en) 2009-08-12
HK1164766A1 (en) 2012-09-28
IN2012DN00804A (el) 2015-06-26
CA3040410C (en) 2023-03-28
NZ620838A (en) 2015-08-28
DK2448637T3 (da) 2014-05-26
EP2448637B1 (en) 2014-03-12
GB2471523A (en) 2011-01-05
ZA201200373B (en) 2012-09-26
CA2766082A1 (en) 2011-01-06
IL217280A0 (en) 2012-02-29
US20120165402A1 (en) 2012-06-28
KR20120088648A (ko) 2012-08-08
US20190247324A1 (en) 2019-08-15
MX2012000257A (es) 2012-01-27
EP3718603A1 (en) 2020-10-07
GB2485291A (en) 2012-05-09
MY156759A (en) 2016-03-31
UA108852C2 (ru) 2015-06-25
PL2448637T5 (pl) 2022-10-03
GB2471565B (en) 2012-07-04
IL217280B (en) 2018-05-31
JP5904938B2 (ja) 2016-04-20
CA3040410A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
CY1115338T1 (el) Χρηση ενος ή ενος συνδυασμου φυτο-κανναβινοειδων στην θεραπεια της επιληψιας
EA201290975A1 (ru) Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии
AR077103A1 (es) Aplicacion de metodos de conocimiento maquinal en la mineria de las reglas de vinculacion en los conjuntos de datos de plantas y animales que contienen indicadores geneticos moleculares, seguido por la clasificacion o prediccion utilizando caracteristicas creadas a partir de estas reglas de vinculac
EA201391733A1 (ru) Каннабиноиды, применяемые для лечения невропатической боли
CL2011002849A1 (es) Composicion anti-inflamatoria que comprende microorganismos sometidos a tratamiento a por lo menos 71,5 grados celsius durante por lo menos 1 segundo; uso de una composicion para tratar o prevenir padecimientos inflamatorios; metodos para proporcionar los microorganismos.
AR080454A1 (es) Fitocanabinoides en el tratamiento del cancer
CL2012000135A1 (es) Alimento inmunoestimulante para peces que contiene pupas de mosca o larvas de moscas.
AR088047A1 (es) Composicion farmaceutica que comprende a los fitocannabinoides cannabidivarina (cbdv) y cannabidiol (cbd)
BRPI0817934A2 (pt) Combinação de lipo-quitooligossacarideo e flavonoide para crescimento de planta e rendimento aumentados
CR11147A (es) Estrobilurinas para aumentar la resistencia de plantas al estres abiotico
BRPI0821003B8 (pt) método para aumentar a imunorreatividade
ECSP099616A (es) Estabilización de vitamina b12
CO7200245A2 (es) Planta de tratamiento de agua con uv con canal abierto
CL2007001514A1 (es) Compuestos derivados de triazina o diazina sustituida por cromano u isocromano, inhibidores de hsp90; composicion farmaceutica que comprende; y su uso en el tratamiento del cancer.
BR112012028559A2 (pt) composições biocidas, e, uso de ésteres de oligoglicerol alcoxilados
ECSP12011996A (es) Moduladores de crth2
BR112012016861A2 (pt) "método para seleção de bactéria com ação antioxidante".
CL2011002651A1 (es) Composicion veterinaria que comprende dipropionato de imidocarb, cianocobalamina vitamina b12 y un vehiculo farmaceuticamente aceptable; y su uso para tratar o prevenir enfermedades infecciosas parasitarias en ganado.
EA201400667A1 (ru) Микробицидная композиция
CL2008001073A1 (es) Uso de una secuencia de acido nucleico que codifica para un homologo tdr4 para obtener un tejido vegetal con contenido alterado de un componente flavonoide.
IT1397708B1 (it) Processo per il trattamento aerobico termofilo di acque di scarico organiche concentrate e relativo impianto.
UY32910A (es) Metodos para preparar medios de nutrición para el crecimiento y/o germinación de los embriones de planta
ECSP13012464A (es) Alimento para alimentación acuícola
BR112012008416A2 (pt) composição de cuidado pessoal, processo para a preparação de um extrato de uma fonte de planta e uso de um extrato de uma fonte de planta
AR081933A1 (es) Compuestos para aumentar la neurogenesis en el tejido neural